On June 30, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 8,591,897...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
PTAB
-
-
On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Over the last two weeks, Pfizer, Inc. (“Pfizer”) has filed petitions for inter partes review (“IPR”) of three additional patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer, Inc. (“Pfizer”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on March 24, 2017, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]